TORII PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,855 JPY | +1.72% |
|
+4.47% | +8.44% |
| Feb. 13 | LIM Advisors Partially Withdraws Shareholder Proposal | CI |
| Feb. 09 | Torii Pharmaceuticals Opposes Shareholder Proposal | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 85,830 | 90,395 | 80,794 | 81,805 | 99,800 | 108,222 | - | - |
| Enterprise Value (EV) 1 | 47,286 | 48,444 | 39,070 | 34,637 | 56,041 | 108,222 | 108,222 | 108,222 |
| P/E ratio | 3.14 x | 25.9 x | 24 x | 20.8 x | 24.2 x | 22.2 x | 19.2 x | 16.1 x |
| Yield | 1.57% | 1.49% | 1.67% | 3.43% | 3.38% | 3.11% | 3.11% | 3.18% |
| Capitalization / Revenue | 2 x | 2.17 x | 1.72 x | 1.67 x | 1.83 x | 1.87 x | 1.77 x | 1.62 x |
| EV / Revenue | 2 x | 2.17 x | 1.72 x | 1.67 x | 1.83 x | 1.87 x | 1.77 x | 1.62 x |
| EV / EBITDA | 35.5 x | 17 x | 15.9 x | 13.6 x | 18.2 x | 17.4 x | 14.2 x | 11.8 x |
| EV / FCF | 2.12 x | 21.6 x | -48.8 x | 42.8 x | -14.5 x | 18.3 x | 19.7 x | 28.7 x |
| FCF Yield | 47.1% | 4.63% | -2.05% | 2.34% | -6.92% | 5.46% | 5.07% | 3.48% |
| Price to Book | 0.76 x | 0.79 x | 0.69 x | 0.69 x | 0.83 x | 0.89 x | 0.88 x | 0.85 x |
| Nbr of stocks (in thousands) | 28,049 | 28,073 | 28,073 | 28,073 | 28,073 | 28,073 | - | - |
| Reference price 2 | 3,060 | 3,220 | 2,878 | 2,914 | 3,555 | 3,855 | 3,855 | 3,855 |
| Announcement Date | 2/6/20 | 2/4/21 | 2/10/22 | 2/10/23 | 2/9/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 42,998 | 41,700 | 46,987 | 48,896 | 54,638 | 57,800 | 61,220 | 66,900 |
| EBITDA 1 | 2,415 | 5,320 | 5,069 | 5,994 | 5,494 | 6,218 | 7,606 | 9,169 |
| EBIT 1 | 1,430 | 4,738 | 4,656 | 5,540 | 5,035 | 6,050 | 7,095 | 8,550 |
| Operating Margin | 3.33% | 11.36% | 9.91% | 11.33% | 9.22% | 10.47% | 11.59% | 12.78% |
| Earnings before Tax (EBT) 1 | 37,700 | 4,225 | 4,767 | 5,722 | 5,593 | 6,550 | 7,592 | 9,060 |
| Net income 1 | 27,367 | 3,495 | 3,374 | 3,944 | 4,119 | 4,885 | 5,652 | 6,730 |
| Net margin | 63.65% | 8.38% | 7.18% | 8.07% | 7.54% | 8.45% | 9.23% | 10.06% |
| EPS 2 | 975.0 | 124.5 | 120.1 | 140.4 | 146.6 | 173.8 | 201.2 | 239.4 |
| Free Cash Flow 1 | 40,400 | 4,182 | -1,654 | 1,912 | -6,902 | 5,913 | 5,485 | 3,770 |
| FCF margin | 93.96% | 10.03% | -3.52% | 3.91% | -12.63% | 10.23% | 8.96% | 5.64% |
| FCF Conversion (EBITDA) | 1,672.88% | 78.61% | - | 31.9% | - | 95.09% | 72.11% | 41.12% |
| FCF Conversion (Net income) | 147.62% | 119.66% | - | 48.48% | - | 121.04% | 97.04% | 56.02% |
| Dividend per Share 2 | 48.00 | 48.00 | 48.00 | 100.0 | 120.0 | 120.0 | 120.0 | 122.5 |
| Announcement Date | 2/6/20 | 2/4/21 | 2/10/22 | 2/10/23 | 2/9/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 S1 | 2021 Q3 | 2022 Q1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 19,857 | 21,555 | 11,882 | 10,960 | 23,102 | 12,213 | 11,811 | 25,699 | 13,433 | 13,451 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 2,738 | 1,788 | 1,365 | 1,292 | 2,682 | 1,384 | -437 | 1,510 | 1,701 | 1,383 |
| Operating Margin | 13.79% | 8.3% | 11.49% | 11.79% | 11.61% | 11.33% | -3.7% | 5.88% | 12.66% | 10.28% |
| Earnings before Tax (EBT) 1 | 2,128 | 1,786 | 1,405 | 1,246 | 2,655 | 1,450 | -405 | 1,540 | 1,772 | 1,160 |
| Net income 1 | 1,800 | 1,244 | 994 | 882 | 1,845 | 1,011 | -288 | 1,086 | 1,282 | 878 |
| Net margin | 9.06% | 5.77% | 8.37% | 8.05% | 7.99% | 8.28% | -2.44% | 4.23% | 9.54% | 6.53% |
| EPS 2 | 64.14 | 44.30 | 35.38 | 31.40 | 65.69 | 35.97 | -10.28 | 38.68 | 45.59 | 31.27 |
| Dividend per Share | 24.00 | 24.00 | - | - | 24.00 | - | - | 50.00 | - | - |
| Announcement Date | 7/31/20 | 7/30/21 | 10/29/21 | 4/28/22 | 7/29/22 | 10/31/22 | 4/28/23 | 7/31/23 | 10/31/23 | 4/26/24 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 38,544 | 41,951 | 41,724 | 47,168 | 43,759 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 40,400 | 4,182 | -1,654 | 1,912 | -6,902 | 5,913 | 5,485 | 3,770 |
| ROE (net income / shareholders' equity) | 27.3% | 3.1% | 2.9% | 3.3% | 3.4% | 3.9% | 4.6% | 5.35% |
| ROA (Net income/ Total Assets) | 1.39% | 3.74% | 3.77% | 4.19% | 3.97% | 3.5% | 4.15% | 4.75% |
| Assets 1 | 1,970,309 | 93,498 | 89,392 | 94,201 | 103,662 | 139,571 | 136,205 | 141,684 |
| Book Value Per Share 2 | 4,029 | 4,098 | 4,165 | 4,243 | 4,274 | 4,312 | 4,402 | 4,520 |
| Cash Flow per Share 2 | 1,010 | 145.0 | 135.0 | 157.0 | 163.0 | 182.0 | 188.0 | 208.0 |
| Capex 1 | 419 | 217 | 150 | 508 | 168 | 1,030 | 1,450 | 1,600 |
| Capex / Sales | 0.97% | 0.52% | 0.32% | 1.04% | 0.31% | 1.78% | 2.37% | 2.39% |
| Announcement Date | 2/6/20 | 2/4/21 | 2/10/22 | 2/10/23 | 2/9/24 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.44% | 688M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4551 Stock
- Financials Torii Pharmaceutical Co., Ltd.
